Innate Pharma SA
Change company Symbol lookup
Select an option...
IPHYF Innate Pharma SA
ROKU Roku Inc
HBAN Huntington Bancshares Inc
AICAF Air China Ltd
BTZ BlackRock Credit Allocation Income Trust
SLG SL Green Realty Corp
SKT Tanger Factory Outlet Centers Inc
SJR Shaw Communications Inc
SJM J M Smucker Co
SJI South Jersey Industries Inc
Go


Based in France
Company profile

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

Closing Price
$4.72
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.72
Day's Low
4.72
Volume
(Heavy Day)
Volume:
200

10-day average volume:
200
200

SHAREHOLDER ALERT: MESO FAF LRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

6:21 am ET November 24, 2020 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Mesoblast Limited (NASDAQ:MESO)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mesoblast-limited-loss-submission-form?prid=11164&wire=1Lead Plaintiff Deadline: December 7, 2020Class Period: April 16, 2019 - October 1, 2020

Allegations against MESO include that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

First American Financial Corp. (NYSE:FAF)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/first-american-financial-corp-loss-submission-form?prid=11164&wire=1Lead Plaintiff Deadline: December 24, 2020Class Period: February 17, 2017 - October 22, 2020

Allegations against FAF include that: (1) the Company failed to implement basic security standards to protect its customers' sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

K12 Inc. (NYSE:LRN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/k12inc-loss-submission-form?prid=11164&wire=1Lead Plaintiff Deadline: January 19, 2021Class Period: April 27, 2020 - September 18, 2020

Allegations against LRN include that: (i) K12 lacked the technological capabilities, infrastructures, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (ii) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer system; (iii) K12 was unable provide the necessary levels of administrative support and training to teachers, students, and parents; and (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted facts.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140Fax. 866.699.3880E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com: https://www.accesswire.com/618177/SHAREHOLDER-ALERT-MESO-FAF-LRN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.